文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

基于HyperSight™ CBCT在前列腺癌根治性放疗中监测肌少症的纵向可行性研究

HyperSightTM-CBCT based monitoring of sarcopenia during definitive radiotherapy of prostate cancer: a longitudinal feasibility study.
PubMed 文献 · Radiat Oncol · 2026-05-29

结果显示CBCT与计划CT的横截面积一致性极好(CCC=0.981),两个队列肌肉密度均显著下降,NF/MHF队列CSA下降>5%在单因素分析中与急性GU毒性相关,但校正后不显著。

要点

  • HyperSight™ CBCT与计划CT的肌肉横截面积一致性极好(CCC=0.981)
  • NF/MHF队列CSA从首分次至末分次显著下降(-153.0 mm²,p=0.021)
  • 两队列肌肉密度(zHU)均显著下降,体重减轻和年龄为独立相关因素

核心结论

  • HyperSight™ CBCT可在前列腺癌放疗中实现骨骼肌定量评估并检测治疗中肌肉密度下降,可能作为肌肉衰减的早期影像标志物。
  • NF/MHF患者中CSA下降>5%在单因素分析中与急性GU毒性相关,但校正年龄、体重减轻、ECOG体能状态和ADT后无显著关联。
  • 研究支持基于CBCT的肌肉监测可行性,需在更大队列中进一步验证。

研究设计与样本

  • 患者接受超低分次(UHF)或常规/中度低分次(NF/MHF)放疗,28%接受雄激素剥夺治疗(ADT)。
  • 在计划CT和系列CBCT(首分次、第二分次、末分次)上评估横截面积(CSA)和放射密度(HU),HU以皮下脂肪进行z标准化(zHU)。
  • 采用一致性相关系数(CCC)、回归和Bland-Altman分析评估PCT与CBCT一致性;混合效应模型分析纵向变化;回归模型分析急性GU/GI毒性(RTOG≥2)关联。

主要发现

  • HyperSight™ CBCT与计划CT的CSA一致性极好(CCC=0.981)。
  • NF/MHF队列显示显著纵向CSA下降(首分次至末分次:-153.0 mm²,p=0.021),UHF队列未见显著组内变化。
  • 两队列肌肉密度(zHU)均显著下降(NF/MHF:p<0.001;UHF:p=0.0017)。
  • 体重减轻和年龄与zHU变化独立相关,未发现CSA下降的独立预测因素。
  • NF/MHF队列中CSA下降>5%在单因素分析中与急性GU毒性相关(OR 4.90,p=0.033;Fisher精确检验p=0.014),校正年龄、体重减轻、ECOG体能状态和ADT后不显著;GI毒性及UHF队列中未发现关联。

关键数值与推荐

  • CSA一致性:CCC=0.981。
  • NF/MHF队列CSA下降:首分次至末分次-153.0 mm²,p=0.021。
  • 肌肉密度下降:NF/MHF p<0.001;UHF p=0.0017。
  • CSA下降>5%与急性GU毒性单因素关联:OR 4.90,p=0.033;Fisher精确检验p=0.014。

临床怎么用

  • HyperSight™ CBCT可用于前列腺癌图像引导放疗期间骨骼肌的定量纵向监测,无需额外成像。
  • 治疗中肌肉密度下降可能作为肌肉衰减的早期影像标志物,值得关注。
  • NF/MHF患者肌肉丢失与急性GU毒性的关联尚属探索性,校正后不显著,暂不能作为临床预测指标。

局限性

  • 肌肉丢失与急性GU毒性的关联仅在单因素分析中显著,校正后不显著,属探索性发现。
  • UHF队列未观察到显著CSA变化,可能受分次方案或随访时间影响。
  • 需在更大队列中进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sarcopenia and treatment-related muscle loss are associated with increased toxicity and reduced resilience in cancer patients. HyperSight™ cone-beam CT (CBCT) provides improved soft-tissue contrast compared with conventional CBCT and may enable reliable longitudinal skeletal-muscle monitoring during image-guided radiotherapy (IGRT). This study evaluated the feasibility of HyperSight™ CBCT-based muscle assessment in prostate cancer patients and explored the clinical relevance of intratreatment muscle decline. METHODS: Eighty-eight patients with non-metastatic prostate cancer were treated on an Ethos® system with HyperSight™ CBCT. Patients received ultrahypofractionated (UHF) or normo-/moderately hypofractionated (NF/MHF) radiotherapy; 28% received androgen-deprivation therapy. Cross-sectional muscle area (CSA) and radiodensity (HU) were assessed on planning CT (PCT) and serial CBCTs (first, second, last fraction [FF, SF, LF]); HU values were z-standardized to subcutaneous fat (zHU). Agreement between PCT and CBCT was evaluated using concordance correlation coefficients (CCC), regression, and Bland-Altman analysis. Longitudinal changes were analyzed using mixed-effects models, and associations with acute genitourinary/gastrointestinal (GU/GI) toxicity (RTOG ≥ 2) using regression models. RESULTS: HyperSight™ CBCT showed excellent agreement with PCT for CSA (CCC = 0.981). The NF/MHF cohort showed a significant longitudinal CSA decline (FF-LF: -153.0 mm², p = 0.021), whereas no significant within-cohort change was observed in UHF. Muscle density (zHU) decreased significantly in both cohorts (NF/MHF: p < 0.001; UHF: p = 0.0017). Weight loss and age were independently associated with zHU change, while no independent predictors of CSA decline were identified. In the NF/MHF cohort, CSA loss > 5% was associated with acute GU toxicity in univariate analysis (OR 4.90, p = 0.033; Fisher's exact p = 0.014), but not after adjustment for age, weight loss, ECOG performance status, and ADT; no associations were found for GI toxicity or in the UHF cohort. CONCLUSIONS: HyperSight™ CBCT enables quantitative skeletal-muscle assessment during prostate radiotherapy and detects intratreatment reductions in muscle density, which may represent an early imaging marker of muscle decline. Muscle loss showed an exploratory association with acute GU toxicity in NF/MHF patients in univariate analysis, but not after adjustment. These findings support the feasibility of CBCT-based muscle monitoring and warrant further evaluation in larger cohorts. CLINICAL TRIAL NUMBER: Not applicable.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Siefert V, V Bettenhausen J, Bicu AS, et al. HyperSightTM-CBCT based monitoring of sarcopenia during definitive radiotherapy of prostate cancer: a longitudinal feasibility study. Radiat Oncol. 2026. PMID: 42216209. doi:10.1186/s13014-026-02856-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。